Slide 1: FY26 Results Presentation
rsonal use only FY26 Results Presentation September 2026 CEO & MD Peter Davey CFO Andrew Allibon
Slide 2: FY26 Financial Highlights
FY26 Financial Highlights Strong performance underpinned by adherence to long-term growth strategy rsonal use only $97.4m 35.5% Revenue ahead of guidance for $92-96m and up 13% on FY25 $86m. Gross margin improvement driven by innovation, product mix and increased benefits from vertical integration R
Slide 3: Operational Highlights – FY26
Operational Highlights – FY26 rsonal use only o Higher demand from infant o CholineXcel – patent has formula customers for Clover’s been registered and high-quality ARA powders. commercial packaging options are being o Melody Dairies delivering profit developed. margin benefits in line with expectat
Slide 4: Product Mix: Successful diversification from innovation
Product Mix: Successful diversification from innovation FY26 rsonal use only o Western manufacturers continue to increase market share o New product sales driven by customer and product diversification o Increased demand for ARA products FY25 o 1H market demand – western manufacturers increased mark
Slide 5: Financials
rsonal use only Financials 5
Slide 6: Profit and Loss FY26
Profit and Loss FY26 FY26 FY25 Profit & Loss Highlights Change $M $M rsonal use only o Revenue increased 13% driven by strong growth in ANZ and EU that more than offset declines in Asia and Americas. Revenue ($m) $97.4 $86.0 +13.3% o The gross profit margin increased to 35.5%, the positive result re
Slide 7: Cash flow FY26
Cash flow FY26 FY26 FY25 Cash flow o Operating cashflow impacted by the deliberate $M $M rsonal use only inventory build of oils and safety stocks of Receipts from customers 105.2 74.8 microencapsulated powders against strong customer forecasts Payments to suppliers and employees (97.1) (64.6) Inter
Slide 8: Balance Sheet July 2026
Balance Sheet 31 July 2026 FY26 FY25 Change Balance Sheet $M $M $M rsonal use only o Strong cash position maintained, reflecting the ongoing investment in inventory (+$19.8m in Cash 7.2 8.7 (1.5) FY26) that was partly offset by improved earnings performance and a more modest Trade Receivables 17.3 2
Slide 9: Operational Highlights
rsonal use only Operational Highlights 9
Slide 10: Ecuador facility: Sustainable Fish Oil Extraction
Ecuador facility: Sustainable Fish Oil Extraction rsonal use only Investment in crude fish oil supply chain is contributing to profit margins gains, with tuna oil steady at 30% of total raw material inputs in FY26. o Continuing to negotiate additional supply of high quality tuna heads. o Ongoing inv
Slide 11: New Zealand: processing and encapsulating of oils
New Zealand: processing and encapsulating of oils rsonal use only Melody Dairies facility Delivering high-quality Melody Dairies is Weekly use by Clover in Pursuing opportunities products with improved operating at near full manufacturing product to maximise outputs to plant use and efficiency capac
Slide 12: CholineXcel
CholineXcel TM o CholineXcel is a unique flowable powder that has broad based rsonal use only commercial applications, with near-term focus on the infant formula and nutraceutical market. o Samples have been presented to selected customers. o Intellectual Property process continues to advance, with
Slide 13: DHA & ARA Growth
DHA & ARA Growth rsonal use only DHA Growth (Omega 3) ARA Growth (Omega 6) • Product diversification into non- • Higher demand from infant formula allergenic, higher fortification levels customers for Clover’s high-quality and plant-based powders have ARA powders allowed Clover to deliver new soluti
Slide 14: USA Nutraceutical Market Development focus
USA USNutraceutical Market nutraceuticals market an emerging Development focus rsonal use only US is the world’s largest nutraceuticals market Clover to use nutraceuticals to spearhead US growth Continued diversification of nutraceuticals formats is positive for Clover’s encapsulation technologies a
Slide 15: Strategy and outlook
rsonal use only Strategy and outlook 15
Slide 16: Strategic focus
Strategic focus 1 Choline – market release, customer acceptance & initial orders & scaled manufacturing and certification rsonal use only 2 USA nutraceutical market development 3 Continued development of our distributor network 4 Investment in facilities & people 5 Continue focused innovation to fur
Slide 17: FY27 Outlook
FY27 Outlook rsonal use only Clover enters FY2027 with positive momentum supported by continued demand for its nutritional products, the benefits of a vertically integrated high- quality supply chain and further expansion of its distribution network. Clover anticipates significant investment in the
Slide 18: Board members
Board members rsonal use only Rupert Harrington Peter Davey Toni Brendish Chair Managing Director & CEO Non-Executive Director Ian Glasson Dr. Simon Green Fiona Pearse Non-Executive Director Non-Executive Director Non-Executive Director 18
Slide 19: Disclaimer
Disclaimer This presentation has been prepared by Clover Corporation Limited (ASX: CLV) (“Clover” or the “Company”) and is provided for information purposes only. The information contained in this presentation is of a general nature and does not constitute financial product advice, investment advice
Slide 20: Q&A
rsonal use only Q&A 20